Sarepta Therapeutics Inc

NASDAQ:SRPTUnited States

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.

Ratings actions from Benzinga: https://www.benzinga.com/quote/SRPT/analyst-ratings

(END) Dow Jones Newswires

November 25, 2024 07:48 ET (12:48 GMT)

This article was automatically generated by Barrons.com using technology from Automated Insights.

With U.S. stock markets set to open in two hours, Dolby Laboratories Inc. Cl A (DLB) was up 12.8% in pre-market trading, and Wix.com Ltd. (WIX) was up 11.0%.

1417 ET - JPMorgan analysts think Sarepta Therapeutics' Duchenne gene therapy is the cure to the stock's low valuation. They say in a research note that investors were disappointed in Sarepta's implied guidance for its Duchenne muscular dystrophy treatment, called Elevidys. But that selloff is a fresh opportunity: They say the stock's valuation is still underappreciating the potential future sales of the treatment. They say that investors are not pricing in the full potential for Elevidys's label expansion, presenting a buying opportunity. The FDA expanded Elevidys's approval to individuals 4 years old and up in June. Shares fall 2.8%. (ben.glickman@wsj.com; @benglickman)